CIK 0001645460 · Non-accelerated filer<br>Smaller reporting company
Cue Biopharma, Inc.
Sign in to watch- Ticker
- CUE
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473324577
- Phone
- 617-949-2680
- Business address
- 100 CHESTNUT STREET, SUITE 300, SOMERVILLE, MA, 02143
- Former names
- Imagen Biopharma, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $389,304
- in 3 filings
Net −$389,304. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 20 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-29 | Warren Lucinda CHIEF BUSINESS OFFICER | Grant or award · Stock Option (right to buy) | +125,000 | 125,000 | ||
| 2025-09-29 | Baker Daniel G. CHIEF DEVELOPMENT OFFICER | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-09-29 | Azam Usman CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (right to buy) | +1,875,000 | 1,875,000 | ||
| 2025-09-26 | Sandercock Colin SVP, GENERAL COUNSEL | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2025-06-04 | Broadfoot Jill Marie Director | Grant or award · Stock Option (right to buy) | +48,800 | 48,800 | ||
| 2025-03-21 | Millar Kerri-Ann CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2025-03-21 | PASSERI DANIEL R CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (right to buy) | +450,000 | 450,000 | ||
| 2025-03-21 | Baker Daniel G. CHIEF DEVELOPMENT OFFICER | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2025-03-21 | Sandercock Colin SVP, GENERAL COUNSEL | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2025-03-21 | Warren Lucinda CHIEF BUSINESS OFFICER | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2025-03-21 | Levisetti Matteo Chief Medical Officer | Grant or award · Stock Option (right to buy) | +250,000 | 250,000 | ||
| 2025-03-10 | Sarraf Pasha Director | Grant or award · Stock Option (right to buy) | +48,800 | 48,800 | ||
| 2025-01-02 | Morich Frank Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2025-01-02 | DRISCOLL FREDERICK W Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2025-01-02 | Kiener Peter A Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2025-01-02 | Verheyen Patrick Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2025-01-02 | Garzone Pamela Director | Grant or award · Stock Option (right to buy) | +24,400 | 24,400 | ||
| 2024-12-16 | PASSERI DANIEL R CHIEF EXECUTIVE OFFICER | Purchase | +30,000 | $1.03 | $31K | 164,578 |
| 2024-11-25 | Baker Daniel G. CHIEF DEVELOPMENT OFFICER | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2024-09-03 | Warren Lucinda CHIEF BUSINESS OFFICER | Grant or award · Stock Option (right to buy) | +350,000 | 350,000 |
Page 4 of 17 · 323 trades